American Heart Association

A large retrospective study of 346,667 patients found that GLP-1 receptor agonists do not increase pancreatitis risk in patients with elevated triglycerides, challenging longstanding clinical concerns.

The META-AF study found that 78% of overweight/obese adults with atrial fibrillation who took metformin after catheter ablation remained free from AFib episodes for one year, compared to 58% in the usual care group.

The OPTIMA-AF trial demonstrated that one month of dual clot-preventing therapy followed by single anticoagulant treatment was as effective as 12 months of dual therapy in preventing stroke, heart attack, and death in AFib patients with coronary stents.

DR10624, a novel triple-receptor agonist targeting FGF21, glucagon, and GLP-1 receptors, demonstrated significant triglyceride reductions of 66-75% across all dose levels in a 12-week Phase II trial.

Milestone Pharmaceuticals will present poster data on etripamil's efficacy, safety, and tolerability for self-administered treatment of paroxysmal supraventricular tachycardia at AHA Scientific Sessions 2025.

A Danish registry study of over 34,000 postmenopausal women found that vaginal estrogen tablets were not associated with increased risk of recurrent ischemic stroke in women with prior stroke history.

The FDA has granted Breakthrough Device Designation to Prevencio's HART CADhs test, an AI-based multi-protein blood test for detecting obstructive coronary artery disease.

A comprehensive meta-analysis of seven randomized controlled trials involving 3,164 patients found that single antiplatelet therapy (SAPT) significantly reduces major bleeding and life-threatening bleeding compared to direct oral anticoagulants after TAVR.

The American Heart Association has funded seven research projects with $1 million to identify which patients with obesity and cardiovascular disease benefit most from GLP-1/GIP medications.

New research reveals that exercising once or twice a week as a "weekend warrior" provides similar cognitive health benefits as more frequent physical activity, potentially reducing mild cognitive impairment risk by 25%.